However, in the latter study, the SP142 antibody was used, which has a lower sensitivity for PD-L1 detection in tumor cells and only ten out of 71 patients (14%) expressed ≥1% PD-L1 in the tumor tissue, which is far less than the expected 50–60% reported in literature [2,45,46]. The gene discussed is CD274; the disease is neoplasm.